Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCAR1 in Relapsed/Refractory GPNMB-Expressing Solid Tumours
NCT07297667Phase 1Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GCAR1 in alveolar soft part sarcoma (ASPS), renal cell carcinoma (RCC) and triple-negative breast cancer (TNBC), sponsored by Canadian Cancer Trials Group. Primary endpoint: Recommended Phase II Dose at 3 years. Started Aug 2026; status: recruiting.
02
Drugs
GCAR1
03
Conditions
alveolar soft part sarcoma (ASPS)renal cell carcinoma (RCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07297667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297667.